Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085540 · ClinicalTrials.gov registry record · Phase 1
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00085540: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00085540 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085540, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth
Interventions
- DRUG depsipeptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00085540
The ClinicalTrials.gov registry entry for NCT00085540 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which depsipeptide is the first listed.
NCT00085540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00085540 about?
NCT00085540 is a clinical study titled "FR901228 in Treating Patients With Recurrent High-Grade Gliomas". This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth
What is the current status of trial NCT00085540?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2005-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00085540?
The interventions under investigation include: depsipeptide (DRUG).
Who is sponsoring clinical trial NCT00085540?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.